심상준 (고려대학교)

한빛사논문

조회253

고려대학교

CV File 932 kb

Biosens. Bioelectron., Jan 23 2024, 250 S0956-5663(24)00064-2 | https://doi.org/10.1016/j.bios.2024.116061 Lateral flow immunoassay based on surface-enhanced Raman scattering using pH-induced phage-templated hierarchical plasmonic assembly for point-of-care diagnosis of infectious disease

Myeong Jin Jeon^a, Soo-Kyung Kim ^b, Sang-Hyun Hwang ^c, Jong Uk Lee ^d, Sang Jun Sim ^a

^aDepartment of Chemical and Biological Engineering, Korea University, 145, Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea

^bDepartment of Laboratory Medicine, Ewha Womans University Mokdong Hospital, Seoul, 09785, Republic of Korea

^cDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea

^dDepartment of Chemical Engineering, Sunchon National University, 225 Jungang-ro, Suncheon, Jeollanam-do, 57922, Republic of Korea

Corresponding authors: Jong Uk Lee, Sang Jun Sim

Abstract

The outbreak of emerging infectious diseases gave rise to the demand for reliable point-of-care testing methods to diagnose and manage those diseases in early onset. However, the current on-site testing methods including lateral flow immunoassay (LFIA) suffer from the inaccurate diagnostic result due to the low sensitivity. Herein, we present the surface-enhanced Raman scattering-based lateral flow immunoassay (SERS-LFIA) by introducing phage-templated hierarchical plasmonic assembly (PHPA) nanoprobes to diagnose a contagious disease. The PHPA was fabricated using gold nanoparticles (AuNPs) assembled on bacteriophage MS2, where inter-particle gap sizes can be adjusted by pH-induced morphological alteration of MS2 coat proteins to provide the maximum SERS amplification efficiency via plasmon coupling. The plasmonic probes based on the PHPA produce strong and reproducible SERS signal that leads to sensitive and reliable diagnostic results in SERS-LFIA. The developed SERS-LFIA targeting severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) antibodies for a proof of concept had <100 pg/mL detection limits with high specificity in serum, proving it as an effective diagnostic device for the infectious diseases. Clinical validation using human serum samples further confirmed that the PHPA-based SERS-LFIA can distinguish the patients with COVID-19 from healthy controls with significant accuracy. These outcomes prove that the developed SERS-LFIA biosensor can be an alternative point-of-care testing (POCT) method against the emerging infectious diseases, in combination with the commercially available portable Raman devices.

논문정보

형식Research article
게재일2024년 01월 (BRIC 등록일 2024-01-31)
연구진국내 연구진
분야 생명과학 > 생물공학

댓글 작성 로그인

CV 열람하기

연락처 보기